Inclusion Criteria:  ≥ 18 and ≤75 years old on day of signing informed consent Signing informed consent Patients with histologically confirmed muscle-invasive bladder cancer (cT2-T4, N0, M0) and with strong intent to bladder sparing(Patients with mixed histology, predominantly transitional cells, could be enrolled. ) Patients must be willing to provide a TURBT specimen during screening and prior to enrollment if adequate specimen (FFPE tissue block or 15 unstained slides) from initial TURBT documenting muscle-invasive urothelial bladder cancer is not available. ECOG performance status of 0 or 1 Adequate organ and marrow function for cisplatin treatment No received prior therapy with systemic chemotherapy or immunotherapy  Exclusion Criteria:  Received prior therapies targeting PD-1, PD-L1, PD-L2, CTLA4, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways Any approved anticancer therapy within 28 days before enrollment Active leptomeningeal disease or uncontrolled, untreated brain metastasis Participants with uncontrolled hypercalcemia Participants with active autoimmune diseases or history of autoimmune diseases that may relapse History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled diseases A known history of HIV infection Prior allogeneic stem cell transplantation or organ transplantation History of severe hypersensitivity reactions to other monoclonal antibodies History of allergic reactions to cisplatin, carboplatin, or other platinum-containing compounds